City

Shanghai (1)

Condition

HER-2 ADC (1)

Kidney Preservation (1)

PD-1antibody (1)

Upper Urinary Tract Urothelial Carcinoma (1)

Overall Status

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

RenJi Hospital (1)

Collaborator

Intervention

rc48 combined with tislelizumab (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

kidney preservation

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC Trial in Shanghai (RC48 Combined With Tislelizumab)

Recruiting

Upper Urinary Tract Urothelial Carcinoma
+3 more

RC48 Combined With Tislelizumab

Shanghai, Shanghai, China

Ethics Committee of Shanghai Renji Hospital

Jun 20, 2023